Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156715 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00156715 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT00156715, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia. The primary hypothesis is that quetiapine treatment will be associated with a decrease in substance use.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00156715
The ClinicalTrials.gov registry entry for NCT00156715 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT00156715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00156715 about?
NCT00156715 is a clinical study titled "Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder". The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia. The primary hypothesis is that quetiapine treatment will be associated with a decrease in substance use.
What is the current status of trial NCT00156715?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2004-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00156715?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00156715?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.